- Home
- PCRX vs STK Comparison
PCRX vs STK Comparison
Compare PCRX & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- STK
- Stock Information
- Founded
- PCRX 2006
- STK 2009
- Country
- PCRX United States
- STK United States
- Employees
- PCRX N/A
- STK N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- PCRX Health Care
- STK Finance
- Exchange
- PCRX Nasdaq
- STK Nasdaq
- Market Cap
- PCRX 604.7M
- STK 567.0M
- IPO Year
- PCRX 2011
- STK N/A
- Fundamental
- Price
- PCRX $18.98
- STK $31.62
- Analyst Decision
- PCRX Buy
- STK
- Analyst Count
- PCRX 10
- STK 0
- Target Price
- PCRX $26.60
- STK N/A
- AVG Volume (30 Days)
- PCRX 933.0K
- STK 38.2K
- Earning Date
- PCRX 11-06-2024
- STK 01-01-0001
- Dividend Yield
- PCRX N/A
- STK 6.60%
- EPS Growth
- PCRX N/A
- STK N/A
- EPS
- PCRX N/A
- STK N/A
- Revenue
- PCRX $694,957,000.00
- STK N/A
- Revenue This Year
- PCRX $4.94
- STK N/A
- Revenue Next Year
- PCRX N/A
- STK N/A
- P/E Ratio
- PCRX N/A
- STK N/A
- Revenue Growth
- PCRX 4.40
- STK N/A
- 52 Week Low
- PCRX $11.16
- STK $24.95
- 52 Week High
- PCRX $35.95
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- PCRX 54.07
- STK 32.62
- Support Level
- PCRX $18.73
- STK $31.33
- Resistance Level
- PCRX $20.34
- STK $36.30
- Average True Range (ATR)
- PCRX 1.13
- STK 0.59
- MACD
- PCRX -0.03
- STK -0.48
- Stochastic Oscillator
- PCRX 64.09
- STK 5.84
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.